DigiStain’s CEO Dr Hemmel Amrania LIVE on Sky NEWS UK

A Digital Solution To Cancer Prognosis cleared by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Digistain is a patented risk profiling test for hormone receptor-positive breast cancer patients.

 

https://www.youtube.com/watch?v=vjfM4onfCX0

Supported by:

royal society logo
NIHR logo
cancer research uk logo
BIVDA logo

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.